PTC Therapeutics (PTCT) News Today $57.14 +0.51 (+0.90%) Closing price 04:00 PM EasternExtended Trading$57.12 -0.02 (-0.04%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period PTC Therapeutics (NASDAQ:PTCT) Sets New 12-Month High - Here's What HappenedPTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week High - Here's What HappenedMarch 21 at 10:07 AM | marketbeat.comPTC Therapeutics presents new data from Phase 3 APHENITY trialMarch 21 at 4:55 AM | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 23,632 shares of the biopharmaceutical company's stock after selMarch 21 at 3:52 AM | marketbeat.comAlphaQuest LLC Sells 21,277 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)AlphaQuest LLC decreased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 95.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,082 shares of the biopharmaceutical company's stock aftMarch 21 at 3:29 AM | marketbeat.comPTC Therapeutics Presents New Sepiapterin Data from Ongoing StudiesMarch 20 at 8:00 AM | prnewswire.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells 5,000 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Stephanie Okey sold 5,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now directly owns 8,867 shares in the company, valued at approximately $478,818. This represents a 36.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 18 at 7:15 PM | marketbeat.comStephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockMarch 18 at 4:21 AM | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. reduced its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 685,709 shares of the biopMarch 17, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $78.00 at JPMorgan Chase & Co.March 17, 2025 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month High on Analyst UpgradeMarch 16, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 15,521 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $53.30, for a total transaction of $827,269.30. Following the completion of the sale, the vice president now owns 103,901 shares in the company, valued at $5,537,923.30. The trade was a 13.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.March 15, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High on Analyst UpgradePTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High on Analyst UpgradeMarch 15, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceJPMorgan Chase & Co. lifted their price target on PTC Therapeutics from $72.00 to $78.00 and gave the stock an "overweight" rating in a research note on Friday.March 15, 2025 | marketbeat.comJPMorgan ups PTC Therapeutics target, adds to Focus ListMarch 14, 2025 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 14, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been given an average rating of "Moderate Buy" by the fifteen brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommMarch 14, 2025 | marketbeat.comBank of America Upgrades PTC Therapeutics (NASDAQ:PTCT) to NeutralMarch 13, 2025 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Upgraded by Bank of America to "Neutral" RatingBank of America upgraded shares of PTC Therapeutics from an "underperform" rating to a "neutral" rating and upped their price objective for the stock from $41.00 to $55.00 in a research report on Tuesday.March 12, 2025 | marketbeat.comGC Wealth Management RIA LLC Purchases Shares of 8,032 PTC Therapeutics, Inc. (NASDAQ:PTCT)GC Wealth Management RIA LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,032 shares of the biopharmaceutical company's stock, valued atMarch 12, 2025 | marketbeat.comB of A Securities Upgrades PTC Therapeutics (PTCT)March 11, 2025 | msn.comSPX Gestao de Recursos Ltda Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)SPX Gestao de Recursos Ltda bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 25,000 shares of the biopharmaceutical company's stock, valued at approximately $1,128,000. Other large inveMarch 11, 2025 | marketbeat.comProficio Capital Partners LLC Acquires Shares of 16,792 PTC Therapeutics, Inc. (NASDAQ:PTCT)Proficio Capital Partners LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 16,792 shares of the biopharmaceutical coMarch 9, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Receives Overweight Rating from Morgan StanleyMorgan Stanley reaffirmed an "overweight" rating and issued a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at ScotiabankScotiabank started coverage on PTC Therapeutics in a report on Friday. They set a "sector perform" rating and a $55.00 price objective on the stock.March 8, 2025 | marketbeat.comCandriam S.C.A. Decreases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Candriam S.C.A. reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 160,109 shares of the biopharmaceutical company's stMarch 8, 2025 | marketbeat.comAigen Investment Management LP Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Aigen Investment Management LP purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,896 shares of the biMarch 8, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $63,369.60 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Allan Steven Jacobson sold 1,230 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total value of $63,369.60. Following the completion of the sale, the director now directly owns 19,118 shares in the company, valued at approximately $984,959.36. The trade was a 6.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.March 7, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 1,230 SharesMarch 7, 2025 | insidertrades.comCantor Fitzgerald Analysts Boost Earnings Estimates for PTCTPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates thatMarch 7, 2025 | marketbeat.comQ1 Earnings Estimate for PTCT Issued By William BlairPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of PTC Therapeutics in a research report issued to clients and investors on Friday, February 28th. William Blair analyst S. Corwin forecasts that theMarch 3, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their EstimatesMarch 2, 2025 | finance.yahoo.comPTC Therapeutics (NASDAQ:PTCT) Hits New 1-Year High - Here's WhyPTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week High - Here's What HappenedMarch 2, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst DowngradePTC Therapeutics (NASDAQ:PTCT) Shares Gap Down Following Analyst DowngradeMarch 1, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $72.00JPMorgan Chase & Co. dropped their price target on PTC Therapeutics from $74.00 to $72.00 and set an "overweight" rating for the company in a research report on Friday.March 1, 2025 | marketbeat.comWe Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) SoonMarch 1, 2025 | finance.yahoo.com5,091 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Ieq Capital LLCIeq Capital LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,091 shares of the biopharmaceutical company'March 1, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Beats Estimates By $0.88 EPSPTC Therapeutics (NASDAQ:PTCT - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.88.February 28, 2025 | marketbeat.comPTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...February 28, 2025 | finance.yahoo.comPTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comPTC Therapeutics reports Q4 EPS (85c), consensus (65c)February 27, 2025 | markets.businessinsider.comPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | prnewswire.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells 795 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 795 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $39,829.50. Following the completion of the transaction, the executive vice president now directly owns 77,856 shares in the company, valued at $3,900,585.60. This represents a 1.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.February 22, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Sells $44,037.90 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CAO Christine Marie Utter sold 879 shares of PTC Therapeutics stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the transaction, the chief accounting officer now owns 63,442 shares of the company's stock, valued at approximately $3,178,444.20. This represents a 1.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.February 22, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Sells $58,516.80 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CFO Pierre Gravier sold 1,168 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $58,516.80. Following the completion of the sale, the chief financial officer now directly owns 75,603 shares in the company, valued at approximately $3,787,710.30. This represents a 1.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 22, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Sells 1,300 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) insider Neil Gregory Almstead sold 1,300 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $65,130.00. Following the sale, the insider now directly owns 101,931 shares in the company, valued at approximately $5,106,743.10. This trade represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.February 22, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,333 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 1,333 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $66,783.30. Following the completion of the sale, the vice president now owns 105,515 shares in the company, valued at approximately $5,286,301.50. This trade represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.February 22, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 1,378 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Eric Pauwels sold 1,378 shares of PTC Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $69,037.80. Following the sale, the chief executive officer now directly owns 85,427 shares of the company's stock, valued at $4,279,892.70. This represents a 1.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.February 22, 2025 | marketbeat.comLee Scott Golden Sells 795 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockFebruary 22, 2025 | insidertrades.comHussman Strategic Advisors Inc. Buys Shares of 21,000 PTC Therapeutics, Inc. (NASDAQ:PTCT)Hussman Strategic Advisors Inc. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,000 shares of the biopharmaceutical company's stockFebruary 22, 2025 | marketbeat.comPTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on ThursdayPTC Therapeutics (NASDAQ:PTCT) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=334330)February 21, 2025 | marketbeat.com Remove Ads Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.400.63▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼146▲PTCT Articles Average Week Remove Ads Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News ITCI News GMAB News MRNA News VTRS News RDY News ASND News SRPT News PCVX News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 3/21/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts